Summary Of Trading Off Bottom - As At Close July 18.

New Post Public Reply Private Reply Replies (0) Message Board

Jul 18, 2019 at 7:35 PM 159

Summary Of Trading Off Bottom - As At Close July 18.

Bought at 1.4001 > 1.6000 [.0008]

Jan 15: 1,750

Total: 1,750

Bought at 1.2001 > 1.4000 [.0007]

Jan 15: 1,247

Total: 1,247

Bought at 1.0001 > 1.2000 [.0006]

Jan 15: 3,179

Total: 3,179

Bought at .8001 > 1.000 [.0005]

Jan 15: 2,484
Jan 16: 1,200
Jan 17: 1,330
Jan 18: 50

Total: 5,064

Bought at .6001 > .7999 [.0003]

Jan 15: 8,027
Jan 16: 2,411
Jan 17: 13,000
Jan 18: 235
Jan 22: 1,000
Jul 10: 20,858 [bid .6100 / ask .6000 > .6475]

Total: 45,531

Bought at .4000 > .5999 [.0002]

Jan 18: 88,566
Jan 22: 16,500
Jan 23: 1,330
Jan 24: 300
Jan 25: 2,040
Jan 29: 6,319
Jan 30: 14,895 [all above .4200 - most around .4400]
Jan 31: 5,877
Feb 1: 8,100
Feb 4: 626
Feb 6: 230
Feb 7: 18,368
Feb 15: 674
Feb 19: 1,926 [all at .4200 / .4300]
Feb 20: 4,127 [all at .4425 > .4500]
Feb 22: 3,370 [.4500 / .4600 / .4999 / 2000 at .5267]
Feb 25: 25,902 [16,859 .4600 > .5000 / 5,660 .5200 > .5985]
Feb 26: 21,078 [18,778 .4750 > .4975 / 2,300 .5050 > .5500]
Feb 27: 10,350 [6,200 .4500 > .4780 / 1,250 .5100 > 5775]
Feb 28: 18,050 [11,500 .4600 > .4999 / 950 .5000 > .5999]
Mar 1: 6,981 [all .4060 / .4100 / .4600]
Mar 4: 200 [all .4900 / .5100]
Mar 5: 80 [all .5100]
Mar 6: 10,522 [7,800 - 73% .5100]
Mar 7: 200 [50% .4700 / 50% .5100]
Mar 8: 23,820 [19,900 .4450 > .4700 / 3,920 .5100]
Mar 11: 3,818 [.4000 / .4500 / .5000]
Mar 12: 7,390 [1,800 .4500 / 5,410 .5000/.5100]
Mar 13: 78,449 [0 < .4500 / 46,898 .4900 > .5800 / 10,300 .5500 > .5800]
Mar 14: 2,420 [.4950 / .5100 / .5200]
Mar 15: 11,638 [.4900 / .5399 / .5400]
Mar 18: 2,848 [1,000 .5000 / 1,000 .5100 / 650 .5300]
Mar 19: 1,155 [.5205/.5524]
Mar 20: 902 [.5350/.5400]
Mar 21: 6,200 [.5400/.5790]
Mar 22: 14,918 [5,580 .5100 > .5699]
Mar 25: 9,645 [.5100 > .5979 / 8,074 .5499 / .5500]
Mar 26: 6,975 [4,000 .4850 > .4979 / 2,825 .5017 > .5970]
Mar 27: 2,959 [1,000 .5500 / 1,303 .5950]
Mar 28: 10,384 [3,850 .5500 > .5620 / 4,384 .5900 > .5950]
Mar 29: 4,788 [4,200 .5600 > .5700]
Apr 1: 20,085 [1,169 .5474 > .5789 / 5,250 .5800 / 10,200 .5900 > .5999]
Apr 2: 5,744 [2,150 .5200 > .5499 / 2,698 .5500 > .5900]
Apr 3: 20,479 [5,045 .5300 > .5500 / 7,533 .5600 > .5790 / 5,499 .5999]
Apr 4: 15,848 [7,933 .5000 / 4,915 .5100 > .5400 / 3000 .5600]
Apr 5: 1,799 [all .5000 > .5290]
Apr 8: 6,740 [ all .5000 > .5700]
Apr 9: 1,712 [.5000 / .5400 / 1,000 .5700]
Apr 10: 20,802 [12,851, .5000 / 7,900 .51525 / .5250 / .5300]
Apr 11: 3,953 [all .5250]
Apr 12: 5,255 [1200 .5200 - remainder of ask retreated to .5850]
Apr 15: 5,296 [3,860 .5200]
Apr 16: 4,526 [3,700 .5100/.5250]
Apr 17: 15,970 [ 1,734 .5000 / 2,000 .5100 / 8,070 .5200 > .5400]
Apr 18: 2,400 [400 .5400/.5500 / 1,000 .5850]
Apr 22: 1,815 [1,010 .5300]
Apr 23: 5,711 [4,071 .4750 / 1,640 .5000 > .5300]
Apr 24: 3,678 [3,025 .4800 > .5000 hidden bid / 600 .5150 > .5400]
Apr 25: 875 [.4800 > .5100]
Apr 26: 8,333 [8,265 .5100]
Apr 29: 14,119 [.4500 hidden bid > .5700]
Apr 30: 3,080 [.4500 hidden bid > .5100]
May 1: 308 [.5100 > .5148]
May 2: 1,704 [hidden bid .4500 > .5350]
May 3: 323 [hidden bid .4500 > .5300]
May 6: 675 [hidden bid .4500]
May 7: 2,082 [hidden bid .4500 / 100 .5100 / 1,772 .5288 > .5300]
May 8: 2,036 [hidden bid .4500 / 1,981 .5100 > .5250]
May 9: 625 [hidden bid .4500 / 250 .5139 > .5200]
May 10: 14,022 [visible bid .4500 then .4600 > .5200]
May 13: 968 [hidden bid .4500 / .5100 > .5200]
May 14: 3,737 [hidden bid .4500 / 2,119 .5100 > .5200]
May 15: 1,845 [hidden bid .5000 / .5100]
May 16: 3,984 [hidden bid .5000 / .5150]
May 17: 250 [hidden bid .5000]
May 20: 924 [hidden bid .4550 / 823 .5100
May 22: 41 [hidden bid .4550]
May 23: 279 [hidden bid .4550]
May 24: 4,312 [hidden bid .4550 / 555 .5100]
May 28: 700 [hidden bid .4550 / 100 .5100]
May 29: 298 [hidden bid .4550 / 100 .5100]
May 30: 3,723 [hidden bid .4550 / 200 .5100]
May 31: 301 [200 hidden bid .5000 / 100 .5100]
Jun 4: 50 [hidden bid .4800]
Jun 7: 40,950 [almost all at hidden bid .4977l]
Jun 8: 72 [hidden bid .4977]
Jun 10: 10,351 [hidden bid .4700 - most filled at .4050]
Jun 11: 580 [hidden bid .4800]
Jun 12: 9,482 [hidden bid .4875 / 3,828 .4900]
Jun 13: 205 [hidden bid .4000 / 200 .4900]
Jun 14: 215 [200 .4900]
Jun 17: 5,000 [hidden bid .4000 / 2,500 .4300]
Jun 18: 200 [hidden bid .4000 / all buys .4900]
Jun 19: 21 [all bought by invisible bidder at .4000]
Jun 21: 300 [all bought by invisible bidder at .4000]
Jun 24: 2,651 [hidden bid at .4750 - 2,600 bought at .4750/.4800]
Jun 25: 1,647 [new bid .4200 ]
Jun 26: 5,131 [bid .4000 / ask .4800]
Jun 27: 52 [bid .4000 / ask .4800]
Jun 28: 10,651 [bid .4200 / ask .4800]
Jul 1: 78 [hidden bid .4000 / ask .4700]
Jul 2: 24,716 [almost all at .4700 / .4900]
Jul 5:31,545 [bid .4600 / ask .5100]
Jul 8: 28,314 [bid .4600 / ask .5100]
Jul 9: 52,137 [bid .5400 / ask .5800]
Jul 10: 69,063 [.5550 bid > .5999 ask]
Jul 11: 17,879 [.5285 > .5575]
Jul 12: 12,035 [.5202 > .5500]
Jul 15: 3,740 [bid .2400 / ask .5799]
Jul 16: 47,500 [bid .5600 / ask .5799]
Jul 17: 13,880 [bid .5560 / ask .5899]
Jul 18: 11,692 [bid .5600 / ask .5899]

Total: 1,017,000

Bought at .2310 > .3999:

Jan 15: 10,418 [all at .0380 - .0002 equivalent]
Jan 18: 22,269
Jan 23: 16,052 [mostly .0370/.0380/.3999]
Jan 24: 18,089 [mostly .0380/.0399]
Jan 25: 17,456 [mostly .0370/.0380]
Jan 28: 23,054 [mostly .0360/.0370/.0390]
Jan 29: 4,189 [mostly at .3900]
Jan 31: 3,001 [all around .3700]
Feb 1: 230 [at .0380]
Feb 4: 4,090 [all at .3800/.3825/.3900]
Feb 5: 6,334 [all at .3800/.3801/.3825]
Feb 6: 222 [all at .3800/.3801/.3813]
Feb 7: 3,144 [all at .3800/.3850]
Feb 8: 71,730 [mostly at .3400/.3800]
Feb 11: 19,719 [ask was .3300/.3400]
Feb 12: 763 [paint downs under ask .3300]
Feb 13: 13,675 [mostly at .3300 >.3425 - then none available < .4000]
Feb 14: 1,146 [all at .3350 > .4000 - then none available < .4200]
Feb 15: 6,608 [almost all at .3900 - then none available <.4300]
Feb 19: 7,356 [all at .3500 or 3837/.3975]
Feb 20: 1,200 [only 200/250/500 at .3025 > .3200]
Feb 21: 990 [only 830/55/105 at .3025 > .3100]
Feb 22: 4,567 [1 at .3100 open p/d - then .3250/.3420/.3480/.3500/.3550]
Mar 1: 5,500 [all .3900 / .3905]
Mar 4: 277 [all .3900]
Mar 5: 186 [all .3900]
Mar 6: 113 [.3900]
Mar 11: 1,125 [paints below extant .3900 bid]
Mar 12: 3,128 [paints below extant .3900 bid]

Total: 239,237

Assume following worst case prior from loading on January 14:

Bought at 1.000 [.0005]: 10,000 [20M] [estimate]

Bought at .8000 [.0004]: 23,000 [46M] [estimate]

Bought at .6000 [.0003]: 50,000 [100M] [estimate]

Bought at .4000 [.0002] 200,000 [400M] [estimate]

Total: 283,000 [566M] [precise]

Enviro-Serv, Inc. (EVSV) Stock Research Links

EVSV Board Company Profile Buy Rating Time & Sales News Filings Financials

"Per Ardua Ad Astra" - "Through Adversity To The Stars"

A very apposite motto for those who trade successfully in the OTC market..

All posts are my opinion - trade at your own risk.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...